Effects of gamma-IFN and NGF on subpopulations in a human neuroblastoma cell line: flow cytometric and morphological analysis.
Neuroblastomas are neural crest-derived tumors that contain neuronal, melanocyte, and Schwann cell precursors. We examined the effects of treatment with gamma-interferon (gamma-IFN) and nerve growth factor (NGF), alone, and in combination, on these progenitor subpopulations in the human neuroblastoma cell line, SH-SY5Y. Using fluorescence-activated flow cytometry (FACS), changes in expression of three differentiation-specific or -associated marker proteins, the 200 kD neurofilament protein, the myelin basic protein, and the S-100 protein, were analyzed. Growth rates and morphological changes associated with each treatment over the 2-wk incubation period were noted. The greatest effects were observed with combined IFN + NGF treatment. These were significant increases in expression of all three proteins, distinctive morphological signs of differentiation, and extensive inhibition of proliferation compared to control cultures. Treatment with NGF alone resulted in increased neurofilament protein expression and in the length and number of neurite extensions, but there was no effect on the growth rate. IFN induced striking morphological changes, significant inhibition of growth, and changes in protein expression that correlated with neuronal to non-neuronal subpopulation shifts due to the death of differentiated cells. When treatment was discontinued after 15 d, the morphological changes induced by NGF were reversed within 2-3 d, while those induced by IFN +/- NGF were present up to 4 wk post-treatment. Small, neuroblastic colonies were observed throughout the treatment period and within 4-6 wk after the cessation of treatment this cell-type fully reconstituted the cultures suggesting the presence of a stem cell. Our results indicate that treatment with gamma-IFN +/- NGF can regulate growth and induce, either stem cells or progenitor neuronal, Schwann and melanocyte subpopulations in the SH-SY5Y cell line to irreversibly differentiate.
Ridge
J
J
Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland 20892, USA.
Terle
D A
DA
Dragunsky
E
E
Levenbook
I
I
D002455:Cell Division; D005434:Flow Cytometry; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology*; D008544:Melanocytes / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D004676:Myelin Basic Protein / Q000378:metabolism; D009414:Nerve Growth Factors / Q000494:pharmacology*; D009432:Neural Crest / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D009447:Neuroblastoma / Q000473:pathology*; D016900:Neurofilament Proteins / Q000378:metabolism; D009474:Neurons / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D009418:S100 Proteins / Q000378:metabolism; D012583:Schwann Cells / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D013234:Stem Cells / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure; D014407:Tumor Cells, Cultured
D004676:Myelin Basic Protein; D009414:Nerve Growth Factors; D016900:Neurofilament Proteins; D009418:S100 Proteins; D007371:Interferon-gamma